illumina inc. - ILMN
ILMN
Close Chg Chg %
212.93 -3.38 -1.59%
Closed Market
209.55
-3.38 (1.59%)
Volume: 1.73M
Last Updated:
Nov 12, 2026, 4:00 PM EDT
Company Overview: illumina inc. - ILMN
ILMN Key Data
| Open $204.41 | Day Range 197.81 - 211.75 |
| 52 Week Range 112.65 - 309.35 | Market Cap $32.49B |
| Shares Outstanding 151.20M | Public Float 150.68M |
| Beta 1.47 | Rev. Per Employee N/A |
| P/E Ratio 36.92 | EPS $5.89 |
| Yield 0.00% | Dividend $3.11 |
| EX-DIVIDEND DATE Jun 25, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.30M |
ILMN Performance
| 1 Week | -0.09% | ||
| 1 Month | -23.45% | ||
| 3 Months | 11.55% | ||
| 1 Year | 76.46% | ||
| 5 Years | -43.04% |
ILMN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
24
Full Ratings ➔
About illumina inc. - ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
ILMN At a Glance
Illumina, Inc.
5200 Illumina Way
San Diego, California 92122
| Phone | 1-858-202-4500 | Revenue | 4.34B | |
| Industry | Medical Specialties | Net Income | 850.00M | |
| Sector | Health Technology | Employees | 8,600 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ILMN Valuation
| P/E Current | 37.931 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 24.767 |
| Price to Sales Ratio | 4.853 |
| Price to Book Ratio | 7.583 |
| Price to Cash Flow Ratio | 19.51 |
| Enterprise Value to EBITDA | 19.376 |
| Enterprise Value to Sales | 5.065 |
| Total Debt to Enterprise Value | 0.116 |
ILMN Efficiency
| Revenue/Employee | 504,418.605 |
| Income Per Employee | 98,837.209 |
| Receivables Turnover | 4.913 |
| Total Asset Turnover | 0.67 |
ILMN Liquidity
| Current Ratio | 2.075 |
| Quick Ratio | 1.719 |
| Cash Ratio | 1.03 |
ILMN Profitability
| Gross Margin | 66.69 |
| Operating Margin | 19.917 |
| Pretax Margin | 25.035 |
| Net Margin | 19.594 |
| Return on Assets | 13.13 |
| Return on Equity | 33.359 |
| Return on Total Capital | 16.111 |
| Return on Invested Capital | 18.649 |
ILMN Capital Structure
| Total Debt to Total Equity | 93.757 |
| Total Debt to Total Capital | 48.389 |
| Total Debt to Total Assets | 38.426 |
| Long-Term Debt to Equity | 72.567 |
| Long-Term Debt to Total Capital | 37.453 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Illumina Inc. - ILMN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.58B | 4.50B | 4.36B | 4.34B | |
Sales Growth
| +1.28% | -1.75% | -3.26% | -0.44% | |
Cost of Goods Sold (COGS) incl D&A
| 1.61B | 1.75B | 1.51B | 1.45B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 394.00M | 432.00M | 354.00M | 270.00M | |
Depreciation
| 215.00M | 235.00M | 224.00M | 203.00M | |
Amortization of Intangibles
| 179.00M | 197.00M | 130.00M | 67.00M | |
COGS Growth
| +17.49% | +8.81% | -13.91% | -4.30% | |
Gross Income
| 2.97B | 2.75B | 2.85B | 2.89B | |
Gross Income Growth
| -5.77% | -7.47% | +3.53% | +1.62% | |
Gross Profit Margin
| +64.83% | +61.06% | +65.34% | +66.69% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.62B | 2.84B | 2.46B | 2.03B | |
Research & Development
| 1.32B | 1.33B | 1.17B | 951.00M | |
Other SG&A
| 1.30B | 1.51B | 1.29B | 1.08B | |
SGA Growth
| -8.72% | +8.63% | -13.43% | -17.59% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 4.65B | 998.00M | 1.52B | (290.00M) | |
EBIT after Unusual Expense
| (4.29B) | (1.09B) | (1.14B) | 1.15B | |
Non Operating Income/Expense
| (18.00M) | 52.00M | 59.00M | 33.00M | |
Non-Operating Interest Income
| 11.00M | 58.00M | 46.00M | 40.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 26.00M | 77.00M | 100.00M | 101.00M | |
Interest Expense Growth
| -57.38% | +196.15% | +29.87% | +1.00% | |
Gross Interest Expense
| 26.00M | 77.00M | 100.00M | 101.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (4.34B) | (1.12B) | (1.18B) | 1.09B | |
Pretax Income Growth
| -590.50% | +74.24% | -5.55% | +192.11% | |
Pretax Margin
| -94.59% | -24.80% | -27.06% | +25.03% | |
Income Tax
| 68.00M | 44.00M | 44.00M | 236.00M | |
Income Tax - Current - Domestic
| 16.00M | 1.00M | 24.00M | 13.00M | |
Income Tax - Current - Foreign
| 75.00M | 77.00M | 137.00M | 104.00M | |
Income Tax - Deferred - Domestic
| (7.00M) | (39.00M) | (115.00M) | 125.00M | |
Income Tax - Deferred - Foreign
| (16.00M) | 5.00M | (2.00M) | (6.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (4.40B) | (1.16B) | (1.22B) | 850.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (4.40B) | (1.16B) | (1.22B) | 850.00M | |
Net Income Growth
| -677.95% | +73.64% | -5.34% | +169.50% | |
Net Margin Growth
| -96.07% | -25.78% | -28.07% | +19.59% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (4.40B) | (1.16B) | (1.22B) | 850.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (4.40B) | (1.16B) | (1.22B) | 850.00M | |
EPS (Basic)
| -28.051 | -7.3481 | -7.6918 | 5.4839 | |
EPS (Basic) Growth
| -652.19% | +73.80% | -4.68% | +171.30% | |
Basic Shares Outstanding
| 157.00M | 158.00M | 159.00M | 155.00M | |
EPS (Diluted)
| -28.051 | -7.3481 | -7.6918 | 5.4487 | |
EPS (Diluted) Growth
| -655.86% | +73.80% | -4.68% | +170.84% | |
Diluted Shares Outstanding
| 157.00M | 158.00M | 159.00M | 156.00M | |
EBITDA
| 748.00M | 338.00M | 739.00M | 1.13B | |
EBITDA Growth
| +39.29% | -54.81% | +118.64% | +53.45% | |
EBITDA Margin
| +16.32% | +7.50% | +16.96% | +26.14% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 264.842 | |
| Number of Ratings | 24 | Current Quarters Estimate | 1.531 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | 5.419 | |
| Last Quarter’s Earnings | 1.44 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.84 | Next Fiscal Year Estimate | 6.161 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 18 | 13 | 14 | 20 |
| Mean Estimate | 1.53 | 1.35 | 5.42 | 6.16 |
| High Estimates | 1.56 | 1.53 | 5.45 | 6.42 |
| Low Estimate | 1.51 | 1.28 | 5.35 | 5.83 |
| Coefficient of Variance | 1.12 | 5.29 | 0.43 | 2.52 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 9 |
| OVERWEIGHT | 1 | 1 | 2 |
| HOLD | 10 | 10 | 8 |
| UNDERWEIGHT | 2 | 2 | 2 |
| SELL | 2 | 2 | 2 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Illumina Inc. - ILMN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Illumina Inc. - ILMN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 10, 2026 | Pat Leckman SVP, Chief People Officer | 21,120 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $208 per share | 4,392,960.00 |
| Nov 10, 2026 | Steven Barnard SVP, Chief Technology Officer | 40,567 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $208 per share | 8,437,936.00 |
| Nov 10, 2026 | Scott Ericksen VP, Chief Accounting Officer | 14,296 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $208 per share | 2,973,568.00 |
| Nov 10, 2026 | Kevin Pegels Chief of Global Operations | 28,434 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $208 per share | 5,914,272.00 |
| Nov 6, 2026 | Corvex Management LP Director | 526,086 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $226.07 per share | 118,932,262.02 |
| Nov 6, 2026 | Corvex Management LP Director | 488,917 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $238.1 per share | 116,411,137.70 |
| Nov 6, 2026 | Corvex Management LP Director | 489,437 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $232.64 per share | 113,862,623.68 |
| Nov 6, 2026 | Corvex Management LP Director | 491,057 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $229.41 per share | 112,653,386.37 |
| Nov 6, 2026 | Corvex Management LP Director | 496,057 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $227.69 per share | 112,947,218.33 |
| Nov 6, 2026 | Corvex Management LP Director | 497,086 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $226.81 per share | 112,744,075.66 |
| Nov 6, 2026 | Corvex Management LP Director | 536,997 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $225.12 per share | 120,888,764.64 |
| Nov 6, 2026 | Corvex Management LP Director | 538,917 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $241.42 per share | 130,105,342.14 |
| Nov 6, 2026 | Corvex Management LP Director | 541,825 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $240.39 per share | 130,249,311.75 |
| Nov 6, 2026 | Corvex Management LP Director | 551,436 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $239.6 per share | 132,124,065.60 |
| Nov 6, 2026 | Corvex Management LP Director | 594,091 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $238.49 per share | 141,684,762.59 |
| Nov 6, 2026 | Corvex Management LP Director | 701,017 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $237.69 per share | 166,624,730.73 |
| Nov 6, 2026 | Corvex Management LP Director | 753,472 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $237.02 per share | 178,587,933.44 |
| Oct 8, 2026 | Jacob Thaysen Chief Executive Officer; Director | 107,770 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $293.69 per share | 31,650,971.30 |
| Oct 5, 2026 | Keith Arlyn Meister Director | 6,887 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $219.8 per share | 1,513,762.60 |
| Oct 5, 2026 | Scott B. Ullem Director | 11,143 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $219.8 per share | 2,449,231.40 |
Illumina Inc. in the News
What's happening with Trump's tariffs on China, Canada and Mexico?
President Donald Trump's tariff dispute with China, Canada and Mexico over fentanyl smuggling and illegal immigration has led to retaliation by the Chinese government.
Cancer test company says vendor mistakenly sent letters to 400 patients that they may have disease
Grail, Inc. said Friday that it erroneously sent out hundreds of form letters that mistakenly told patients they had cancer when many of them had not yet taken the blood test.